Oncolytics Biotech Inc. (ONCY)

USD 0.74

(-3.76%)

Market Cap (In USD)

57.18 Million

Revenue (In USD)

-

Net Income (In USD)

-27.75 Million

Avg. Volume

178.7 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.73-1.53
PE
-
EPS
-
Beta Value
1.506
ISIN
CA6823108759
CUSIP
682310875
CIK
1129928
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Wayne F. Pisano M.B.A.
Employee Count
-
Website
https://www.oncolyticsbiotech.com
Ipo Date
2001-10-05
Details
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.